PRESS RELEASE:

Spectrum Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Leslie Titus Bryant, Director of Marketing & Brand
January 27, 2021

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity and positive agreement against tissue biopsy-based genotyping. Saliva will be collected, preserved, and transported for DNA testing using Spectrum’s Saliva Collection System. The company will further support the development of clinical methods and additional technical innovations.

The study is being led by professor of oral biology, Dr. David Wong, from the UCLA School of Dentistry, a research-intensive dental school and the lead U.S. research site for the study.

“Saliva-based liquid biopsy ctDNA detection can be used to not only provide an accurate cancer diagnosis, but additionally track the actionable mutations, monitor a response to treatments, and assess the emergence of drug resistance,” Dr. Wong said. “This study’s non-invasive use of saliva for the analysis of ctDNA will prove to overcome current limitations, provide procedures that improve detection sensitivity, and offer significant clinical impact on early detection, risk assessment, screening, diagnosis, and personalized/precision medicine.”

The research study will compare saliva and plasma samples from NSCLC patients to identify usctDNA molecules in saliva and use special extraction methods to improve overall sensitivity of current liquid biopsy procedures.

“At Spectrum Solutions, we are proud to sponsor Dr. Wong and UCLA in this exciting research project to unlock and harness the potential of saliva as a primary diagnostic resource to combat and improve the lives and wellbeing of people around the world,” said Stephen Fanning, President, and CEO of Spectrum Solutions. “We look forward to working with the innovative researchers at UCLA and pledge our full support.”

ABOUT THE UCLA SCHOOL OF DENTISTRY

The UCLA School of Dentistry is dedicated to improving the oral health of the people of California, the nation, and the world. It has an international reputation for its teaching, research, patient care, and public service initiatives. The school provides education and training that develop leaders; conducts research programs that generate new knowledge; and delivers patient‑centered oral health care to the community and state.

PRESS RELEASE:

Spectrum Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Leslie Titus Bryant, Director of Marketing & Brand
January 27, 2021

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity and positive agreement against tissue biopsy-based genotyping. Saliva will be collected, preserved, and transported for DNA testing using Spectrum’s Saliva Collection System. The company will further support the development of clinical methods and additional technical innovations.

The study is being led by professor of oral biology, Dr. David Wong, from the UCLA School of Dentistry, a research-intensive dental school and the lead U.S. research site for the study.

“Saliva-based liquid biopsy ctDNA detection can be used to not only provide an accurate cancer diagnosis, but additionally track the actionable mutations, monitor a response to treatments, and assess the emergence of drug resistance,” Dr. Wong said. “This study’s non-invasive use of saliva for the analysis of ctDNA will prove to overcome current limitations, provide procedures that improve detection sensitivity, and offer significant clinical impact on early detection, risk assessment, screening, diagnosis, and personalized/precision medicine.”

The research study will compare saliva and plasma samples from NSCLC patients to identify usctDNA molecules in saliva and use special extraction methods to improve overall sensitivity of current liquid biopsy procedures.

“At Spectrum Solutions, we are proud to sponsor Dr. Wong and UCLA in this exciting research project to unlock and harness the potential of saliva as a primary diagnostic resource to combat and improve the lives and wellbeing of people around the world,” said Stephen Fanning, President, and CEO of Spectrum Solutions. “We look forward to working with the innovative researchers at UCLA and pledge our full support.”

ABOUT THE UCLA SCHOOL OF DENTISTRY

The UCLA School of Dentistry is dedicated to improving the oral health of the people of California, the nation, and the world. It has an international reputation for its teaching, research, patient care, and public service initiatives. The school provides education and training that develop leaders; conducts research programs that generate new knowledge; and delivers patient‑centered oral health care to the community and state.

Press Release Header- UCLA - DR WONG Research Study Liquid Biopsy for Eary Detection of Lung Cancer

Access this press release on Business Wire

Our Team, Helping your Team, get Back in the Game!

How you collect saliva makes a big diagnostic difference.
Real-world mass testing scenarios require an authorized, proven, and supported system that mitigates any risk of exposure and a company that holds a blackbelt in scalability.
Get your business back in the game.

blank

PROUD PARTNER OF MLB

™/© 2020 MLB

Our Team, Helping Your Team, Get Back in the Game!

How you collect saliva makes a big diagnostic difference. To incorporate the use of saliva into COVID-19 diagnostic testing protocols or implement actual real-world mass-testing in scalable scenarios requires an authorized, proven, validated, and supported system that actually mitigates risk of exposure and a device engineered to increase testing accuracy. Get your business back in the game.

Providing the test kits helping keep MLB™ stars on the field.

PROUD PARTNER OF MLB

blank

Get to know our #partofthesolution

About Spectrum Solutions and Spectrum DNA

Headquartered in Salt Lake City, Utah, Spectrum Solutions and its medical device and services division, Spectrum DNA, focus their concentrated industry expertise on engineering innovative end-to-end solutions for both clinical diagnostic projects and commercial product plans. A single-source provider of on-site medical device development and manufacturing, custom packaging, kitting, and direct-to-consumer fulfillment. Its biosample collection devices, patented technologies, and dedicated services deliver measurable process optimization, unprecedented efficiency, and unmatched global scalability.

#partoftheSolution

Leslie Titus Bryant Spectrum Solutions SpokesmanSpectrum Corporate Spokesman
Leslie Titus Bryant
Director of Marketing & Brand
admin@spectrumsolution.com

Tim Rush Public Relations, Springboard 5Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com

Get to know our #partofthesolution

ABOUT SPECTRUM SOLUTIONS AND SPECTRUM DNA

Headquartered in Salt Lake City, Utah, Spectrum Solutions and its medical device and services division, Spectrum DNA, focus their concentrated industry expertise on engineering innovative end-to-end solutions for both clinical diagnostic projects and commercial product plans. A single-source provider of on-site medical device development and manufacturing, custom packaging, kitting, and direct-to-consumer fulfillment. Its biosample collection devices, patented technologies, and dedicated services deliver measurable process optimization, unprecedented efficiency, and unmatched global scalability.

#partoftheSolution

Leslie Titus Bryant Spectrum Solutions SpokesmanSpectrum Corporate Spokesman
Leslie Titus Bryant
Director of Marketing & Brand
admin@spectrumsolution.com

Tim Rush Public Relations, Springboard 5Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com

Spectrum
in the News

Spectrum
in the News

About the Product

Innovative Engineering

Spectrum-SDNA-1000-Saliva-Collection-Proud Partner of MLB2

Spectrum Solutions has manufactured over 20 million Saliva Collection devices for distribution worldwide. Spectrum’s technically superior  SDNA-1000 saliva collection device was engineered to lead the saliva collection industry in molecular diagnostics and clinical research applications delivering the safest and most robust biomaterial collection approach for the detection and diagnosis of disease or viral infection.

  • First saliva collection device to receive EUA authorization for COVID-19 testing
  • First saliva collection device FDA authorized for at-home sample collection
  • Only pain-free biosample collection option for COVID-19 testing
  • Engineered to reduce self-collection error
  • Delivers consistent high-quality, high-yield biosamples
  • 100% inactivation of the live virus
  • 100% bacteriostatic
  • Delivers over a 90% reduction in PPE usage compared to current swab collections for COVID-19 testing
  • Single device preserves both DNA and fragile viral RNA transcripts
  • Device stabilizes and extends biosample viability post-collection over 10 days with no degradation of sample efficacy extending shipping and transport options
  • Saliva collection system mitigates any risk of infection throughout the testing process
  • Pinpoint life-cycle stage of active viral infection
Questions? Let’s Connect
Spectrum-SDNA-1000-Saliva-Collection-Proud Partner of MLB2

About the Product

Innovative Engineering

Spectrum Solutions has manufactured over 20 million Saliva Collection devices for distribution worldwide. Spectrum’s technically superior  SDNA-1000 saliva collection device was engineered to lead the saliva collection industry in molecular diagnostics and clinical research applications delivering the safest and most robust biomaterial collection approach for the detection and diagnosis of disease or viral infection.

  • First saliva collection device to receive EUA authorization for COVID-19 testing
  • First saliva collection device FDA authorized for at-home sample collection
  • Only pain-free biosample collection option for COVID-19 testing
  • Engineered to reduce self-collection error
  • Delivers consistent high-quality, high-yield biosamples
  • 100% inactivation of the live virus
  • 100% bacteriostatic
  • Delivers over a 90% reduction in PPE usage compared to current swab collections for COVID-19 testing
  • Single device preserves both DNA and fragile viral RNA transcripts
  • Device stabilizes and extends biosample viability post-collection over 10 days with no degradation of sample efficacy extending shipping and transport options
  • Saliva collection system mitigates any risk of infection throughout the testing process
  • Pinpoint life-cycle stage of active viral infection
Questions? Let’s Connect
Contact Us

Let's Connect.

#partofthesolution